Co-founder and CTO Martijn Cox discusses insights on how “the future of heart valve replacement is happening” at Xeltis in a video-interview. Martijn explains Xeltis’ revolutionary approach to cardiovascular regenerative medicine called Endogenous Tissue Restoration (ETR), the natural restoration of complex cardiovascular parts via bioabsorbable heart devices. A PhD graduate from Eindhoven University of Technology, Martijn touches upon the Nobel prize-awarded science that has now translated into Xeltis technology and on how the company is progressing fast to benefit patients and the healthcare system overall.
Martijn Cox_Bringing Xeltis technology to life from XELTIS on Vimeo.
